2 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy.Occult Hepatitis B Infection in Cancer PatientsActive, not recruitingNot stated2025-12-24NCT06347588
DAratumumab and REvlimid REfractory MMBlood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic diseaseRecruitingNot stated2024-08-07NCT06541860